NewsSource: EClinCloud Official Website Archive

EClinCloud Becomes Signant Health's Exclusive Strategic Partner in Greater China

2 min readEClinCloud Editorial Team
Cover image for archival article on EClinCloud becoming Signant Health's exclusive strategic partner in Greater China

To better support the global growth and expansion of Chinese pharmaceutical companies and the shift toward digital clinical trials, EClinCloud Technology Co., Ltd. ("EClinCloud") and Signant Health, a leading global evidence-generation company, have formed an exclusive strategic partnership to jointly promote Signant's SmartSignals eCOA software and services in Greater China. EClinCloud will serve as Signant's exclusive representative for business operations in Greater China, bringing leading clinical development services to sponsors and CROs seeking technology to improve data collection quality.

Headquartered in the United States with more than 1700 employees across three continents, Signant Health focuses on complex neurology and oncology and advances clinical development in neurology, oncology, and other therapeutic areas through a suite of clinical trial technology solutions, scientific services, and collaborations with scientific organizations worldwide.

Clinical trials in China are advancing rapidly, with rapid progress in digitalization. As a global leader in eCOA and endpoint assessment, Signant Health places a strong focus on the patient experience, simplifies every step patients go through in clinical trials, brings deep therapeutic expertise, and has earned the trust and collaboration of hundreds of sponsors and CROs (including all of the top 20 pharmaceutical companies). Signant Health noted that working with EClinCloud will provide Signant with strong local support in Greater China, marking a significant milestone.

EClinCloud's comprehensive, unified clinical research platform includes not only next-generation CTMS, eTMF, EDC, RTSM, and more, but also future-ready solutions such as eCOA. Combined with precision medical evaluation frameworks across therapeutic areas, the platform remains patient-centric and leverages patient engagement to provide greater convenience for patients.

Dr. Qin Long, CEO of EClinCloud, said: "EClinCloud's clinical commercial and clinical services teams bring an international perspective and the capability to deliver services in accordance with international standards. Through this partnership, EClinCloud will establish a leading position in eCOA, scale management, and rater training while enhancing the patient experience. By combining EClinCloud's proprietary products with Signant's scientific and clinical operations expertise, we will help domestic and international pharmaceutical companies and research institutions expand patient access, improve data quality, and bring life-changing therapies to the global community."

About EClinCloud

Guided by its mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a healthcare and life-sciences technology company based in China and serving the world. Through its seamlessly integrated end-to-end unified platform (spanning scale management, linguistic validation, study design, eCOA, EDC, CTMS, eTMF, and more) and precision medical evaluation frameworks across therapeutic areas (oncology, neurology, cardiology, pulmonology, dermatology, and others), EClinCloud is building a globally leading, patient-centric unified clinical evidence support SaaS cloud platform, helping well-known domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.

For more information, please visit: www.eclincloud.com

Related reading

Cover image for archived article: National Innovation Center adopts EClinCloud CTMS and eTMF systems to digitally enable medical device clinical trialsNews3 min readNational Innovation Center for Advanced Medical Devices Adopts EClinCloud CTMS and eTMF Systems to Digitally Enable Medical Device Clinical TrialsOn October 14, EClinCloud (Shenzhen) Technology Co., Ltd. ("EClinCloud") attended the High-End Medical Device Clinical Trials Symposium and Clinical Trial Project Management System Launch Meeting, hosted by the National Innovation Center for Advanced Medical Devices ("the Center"). At the meeting, EClinCloud CEO Dr. Qin Long introduced the clinical trial project management system.Archived article cover: EClinCloud eTMF system supporting Yuanxin Technology in conducting an international multicenter clinical studyNews3 min readEClinCloud eTMF System Supports Biotyx Medical's International Multicenter Clinical StudyEClinCloud (Shenzhen) Technology Co., Ltd. ("EClinCloud") and Biotyx Medical (Shenzhen) Co., Ltd. ("Biotyx Medical") recently announced a deeper collaboration, under which Biotyx Medical is adopting EClinCloud's eTMF (electronic Trial Master File) solution for its international multicenter clinical trial of a below-the-knee bioresorbable scaffold. Using its digital management platform and extensive experience, EClinCloud supports Biotyx Medical's global business development needs to help it become a globally leading cardiovascular medical device company.Archived article cover: EClinCloud completes tens of millions of RMB in Series A financing to accelerate building its clinical evidence support platformNews3 min readEClinCloud Completes Tens of Millions of RMB in Series A Financing to Accelerate Its Clinical Evidence Support PlatformEClinCloud Technology Co., Ltd. ("EClinCloud") recently announced the completion of tens of millions of RMB in Series A financing, exclusively invested by Kangjun Capital. The proceeds will primarily be used to further strengthen its R&D, medical, clinical operations, and clinical data science teams, accelerate the realization of a patient-centric integrated cloud platform, and enhance after-sales service capabilities.